术前伊立替康、顺铂新辅助化疗联合阴式广泛宫颈切除术治疗早期宫颈癌的疗效及安全性评价

Efficacy and safety of preoperative neoadjuvant chemotherapy with irinotecan and cisplatin plus vaginal radical trachelectomy in early cervical cancer

目的评价术前伊立替康、顺铂新辅助化疗联合阴式广泛宫颈切除术(VRT)治疗早期宫颈癌的疗效及安全性。方法84例行VRT的早期宫颈癌年轻患者分为观察组和对照组,观察组采用术前伊立替康、顺铂新辅助化疗,对照组采用术前顺铂新辅助化疗。比较两组手术情况、治疗效果、生活质量、血清肿瘤标志物、术后并发症和不良反应。结果观察组手术时间、术中出血量、尿管拔除时间、术后排气时间、并发症及血清VEGF、CA125、CEA水平均显著低于对照组,尿失禁生活质量问卷(I-QOL)、生存质量调查表(EORTC OLO-C30)和女性性功能量表(FSFI)评分均高于对照组(P<0.01或0.05)。结论伊立替康、顺铂新辅助化疗联合VRT可明显提高早期宫颈癌患者生活质量,减少并发症。

Objective To evaluate the efficacy and safety of preoperative neoadjuvant chemotherapy(NACT)with irinotecan and cisplatin plus vaginal radical trachelectomy(VRT)in early cervical cancer.Methods Eighty-four young patients with early cervical cancer undergoing VRT were treated with preoperative NACT with irinotecan and cisplatin(observation group)or single cisplatin(control group).The operation condition,therapeutic effect,quality of life,serum tumor markers,and postoperative complications and adverse reactions were compared between two groups.Results Compared with control group,operation time,intraoperative bleeding volume,urethral extubation time,postoperative exhaust time and complications,and serum VEGF,CA125 and CEA levels were lower,while I-QOL,EORTC OLO-C30 and FSFI scores were higher in observation group(P<0.01 or 0.05).Conclusion Preoperative NACT with irinotecan and cisplatin plus VRT can improve quality of life and reduce complications in early cervical cancer.